
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics Inc has achieved significant milestones, including FDA clearance for a Phase 2a study and the initiation of the ALSTARS Phase 2 trial for ALS, showcasing its operational effectiveness and commitment to advancing its Treg therapies in neurodegenerative diseases. Promising early clinical data indicates biomarker improvement and disease progression signals, reinforcing the potential efficacy of its proprietary therapies and validating the underlying Treg biology. With a robust cash position of $46.8 million, the company is well-funded to support its operations through the second half of 2027, enhancing its strategic positioning for continued growth in a competitive biotechnology landscape.
Bears say
Coya Therapeutics Inc faces significant challenges that negatively impact its stock outlook, including the potential for delays in regulatory approval and commercial uptake for its lead product, COYA 302, particularly in conditions such as ALS and Alzheimer's disease. The company is also experiencing risks related to its pipeline candidates, with setbacks threatening to hinder progress and advancement into pivotal development stages. Additionally, issues surrounding partnerships and the possibility of medium-term equity dilution present further pressures on Coya's financial stability and market performance.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares